m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05380
 [1]
m6A modification hsa-miR-873-5p hsa-miR-873-5p METTL3 Methylation : m6A sites Direct Enhancement Non-coding RNA miR-873-5p KEAP1  lncRNA       miRNA   circRNA
m6A Modification:
m6A Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
m6A Target hsa-miR-873-5p
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator hsa-miR-873-5p microRNA View Details
Regulated Target Kelch-like ECH-associated protein 1 (KEAP1) View Details
Crosstalk Relationship m6A  →  ncRNA Enhancement
Crosstalk Mechanism m6A regulators directly modulate the functionality of ncRNAs through specific targeting ncRNA
Crosstalk Summary METTL3 interacts with the microprocessor protein DGCR8 and positively modulates hsa-miR-873-5p mature process in an m6A-dependent manner. METTL3/m6A in colistin-induced nephrotoxicity and provide a new insight on m6A modification in drug induced toxicity. Further experiments show that miR-873-5p could regulate Kelch-like ECH-associated protein 1 (KEAP1)-Nrf2 pathway against colistin-induced oxidative stress and apoptosis.
Responsed Disease Diseases of the urinary system ICD-11: GC2Z
 Disease Info 
Pathway Response Apoptosis hsa04210
Cell Process Oxidative stress and apoptosis
In-vitro Model
 mRTEC (Mouse renal tubular epithelial cells)
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Kelch-like ECH-associated protein 1 (KEAP1) 35 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name CXA10 Phase 2 [2]
MOA Inactivator
External Link
TTD: DF1JO7
 Compound Name PMID28454500-Compound-8 Patented [3]
MOA Modulator
Activity IC50(RAW264.7 cells) = 1 nM
External Link
CID: 66546002
TTD: D01GTU
 Compound Name Pyrazino[2,1-a]isoquinolin derivative 4 Patented [3]
Synonyms
PMID28454500-Compound-31
    Click to Show/Hide
MOA Modulator
External Link
TTD: D01MZI
 Compound Name PMID28454500-Compound-36 Patented [3]
MOA Modulator
External Link
CID: 121289252
TTD: D01PKZ
 Compound Name Chalcone derivative 4 Patented [3]
Synonyms
PMID28454500-Compound-19
    Click to Show/Hide
MOA Modulator
External Link
CID: 118567653
TTD: D02SPI
 Compound Name 2-hydroxybenzamide derivative 1 Patented [3]
Synonyms
PMID28454500-Compound-38
    Click to Show/Hide
MOA Modulator
External Link
TTD: D02YNU
 Compound Name Vinyl sulfone derivative 1 Patented [3]
Synonyms
PMID28454500-Compound-20
    Click to Show/Hide
MOA Modulator
External Link
CID: 73053707
TTD: D04ILM
 Compound Name Pyrazino[2,1-a]isoquinolin derivative 2 Patented [3]
Synonyms
PMID28454500-Compound-29
    Click to Show/Hide
MOA Modulator
External Link
TTD: D06LEF
 Compound Name Diterpenoid derivative 1 Patented [3]
Synonyms
PMID28454500-Compound-47
    Click to Show/Hide
MOA Modulator
Activity EC50 < 500 nM
External Link
CID: 132210477
TTD: D09FZF
 Compound Name PMID28454500-Compound-13 Patented [3]
MOA Modulator
Activity IC50 = 0.8 nM
External Link
CID: 73335601
TTD: D0AJ2T
 Compound Name PMID28454500-Compound-12 Patented [3]
MOA Modulator
External Link
TTD: D0AX4Q
 Compound Name Pyrazino[2,1-a]isoquinolin derivative 1 Patented [3]
Synonyms
PMID28454500-Compound-28
    Click to Show/Hide
MOA Modulator
External Link
TTD: D0AZ8T
 Compound Name PMID28454500-Compound-41 Patented [3]
MOA Modulator
External Link
CID: 11000442
TTD: D0C1PB
 Compound Name Chalcone derivative 2 Patented [3]
Synonyms
PMID28454500-Compound-17
    Click to Show/Hide
MOA Modulator
External Link
CID: 118567519
TTD: D0EO3S
 Compound Name PMID28454500-Compound-34 Patented [3]
MOA Modulator
External Link
CID: 121289250
TTD: D0FH6P
 Compound Name PMID28454500-Compound-33 Patented [3]
MOA Modulator
External Link
CID: 121289344
TTD: D0FM3Q
 Compound Name Chalcone derivative 3 Patented [3]
Synonyms
PMID28454500-Compound-18
    Click to Show/Hide
MOA Modulator
External Link
TTD: D0G1LS
 Compound Name PMID28454500-Compound-50 Patented [3]
MOA Modulator
External Link
CID: 193653
TTD: D0G4EK
DrugBank: DB04339
 Compound Name PMID28454500-Compound-3 Patented [3]
MOA Modulator
External Link
TTD: D0JH8Z
 Compound Name Pyridyl compound 1 Patented [3]
Synonyms
PMID28454500-Compound-15
    Click to Show/Hide
MOA Modulator
Activity IC50 = 4.3 nM
External Link
TTD: D0KX0J
 Compound Name PMID28454500-Compound-32 Patented [3]
MOA Modulator
External Link
CID: 121289291
TTD: D0L1JQ
 Compound Name PMID28454500-Compound-40 Patented [3]
MOA Modulator
External Link
CID: 5316743
TTD: D0MQ3X
 Compound Name PMID28454500-Compound-35 Patented [3]
MOA Modulator
External Link
CID: 121289348
TTD: D0MX0Q
 Compound Name PMID28454500-Compound-49 Patented [3]
MOA Modulator
External Link
TTD: D0N1VC
 Compound Name PMID28454500-Compound-9 Patented [3]
MOA Modulator
Activity IC50(RAW264.7 cells) = 0.7 nM
External Link
CID: 66546189
TTD: D0N9GH
 Compound Name Diterpenoid derivative 2 Patented [3]
Synonyms
PMID28454500-Compound-48
    Click to Show/Hide
MOA Modulator
Activity EC50 < 500 nM
External Link
CID: 132210549
TTD: D0Q9QQ
 Compound Name PMID28454500-Compound-11 Patented [3]
MOA Modulator
External Link
CID: 68066028
TTD: D0RM4V
 Compound Name PMID28454500-Compound-37 Patented [3]
MOA Modulator
External Link
CID: 121289347
TTD: D0SA1N
 Compound Name Chalcone derivative 1 Patented [3]
Synonyms
PMID28454500-Compound-16
    Click to Show/Hide
MOA Modulator
External Link
CID: 53262706
TTD: D0U9TR
 Compound Name Pyrazino[2,1-a]isoquinolin derivative 3 Patented [3]
Synonyms
PMID28454500-Compound-30
    Click to Show/Hide
MOA Modulator
External Link
TTD: D0VA2G
 Compound Name 2-hydroxybenzamide derivative 2 Patented [3]
Synonyms
PMID28454500-Compound-39
    Click to Show/Hide
MOA Modulator
External Link
TTD: D0VW9H
 Compound Name PMID28454500-Compound-10 Patented [3]
MOA Modulator
External Link
CID: 68066062
TTD: D0WN1Y
 Compound Name Trepenoid derivative 1 Patented [3]
Synonyms
PMID28454500-Compound-14
    Click to Show/Hide
MOA Modulator
External Link
TTD: D0XL2V
 Compound Name VCB101 Preclinical [4]
MOA Inactivator
External Link
TTD: D46EBX
 Compound Name VCB102 Preclinical [4]
MOA Inactivator
External Link
TTD: DG07UD
GC2Z: Diseases of the urinary system 32 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Diatrizoate Approved [5]
Synonyms
Diatrizoate sodium
    Click to Show/Hide
External Link
CID: 2140
TTD: D0T9DT
DrugBank: DB00271
 Compound Name Voclosporin Phase 3 [6]
Synonyms
Luveniq; ISAtx-247; ISA-247; UNII-2PN063X6B1; ISATX247; 515814-01-4; ISA247; 2PN063X6B1; ISA 247; trans-ISA-247; LX211; Voclosporin (USAN/INN); Voclosporin [USAN:INN]; Voclera; 3odi; LX-211; LX-214; ISA247, Luveniq; AC1OCFHS; R-1524; SCHEMBL12632344; CHEBI:135957; (E)-ISA-247; DB11693; 515814-00-3; HY-106638; CS-0026210; D09033; Cyclosporin A, 6-((2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)-6,8-nonadienoic acid)-; 368455-04-3; Voclosporin [USAN]; R 1524; Trans-ISA 247; TrkA-IgG
    Click to Show/Hide
External Link
CID: 6918486
TTD: D0L9HX
DrugBank: DB11693
 Compound Name Mesna Approved [5]
Synonyms
Mesnex; Mexan; Mitexan; Uromitexan; Mesna, Shionogi; S-7878; 2-mercaptoethane sulfonate
    Click to Show/Hide
External Link
CID: 23662354
TTD: D0C3YQ
 Compound Name Phloroglucinol Approved [5]
Synonyms
108-73-6; Benzene-1,3,5-triol; 1,3,5-trihydroxybenzene; 1,3,5-benzenetriol; Phloroglucin; Phloroglucine; Spasfon-Lyoc; s-Trihydroxybenzene; 5-Hydroxyresorcinol; Benzene-s-triol; 3,5-Dihydroxyphenol; Benzene, trihydroxy; sym-Trihydroxybenzene; 5-Oxyresorcinol; Dilospan S; Floroglucinol; Floroglucin; Phloroglucinol anhydrous; 5-Oxyresorcinolphloroglucin; 1,3,5-THB; 1,3,5-Trihydroxycyclohexatriene; 1,3,5-Triol; Floroglucin [Czech]; Floroglucinol [Czech]; Benzene, 1,3,5-trihydroxy-; UNII-DHD7FFG6YS; 5-Benzenetriol; NSC 157
    Click to Show/Hide
External Link
CID: 359
TTD: D07EXH
DrugBank: DB12944
 Compound Name Aminohippurate sodium Approved [5]
Synonyms
p-Aminohippurate sodium; Sodium p-aminohippurate; 94-16-6; Sodium 4-aminohippurate; Natrium 4-aminohippurat; Aminohippuric acid Sodium salt; Sodium para-Aminohippurate; Ammohippurate sodium; Monosodium p-aminohippurate; Amino-hippurate-sodium; p-Aminohippuric acid sodium salt; UNII-SUO3KVS1O9; Paraaminohippurate Injection; 4-Aminohippursaeure, natriumsalz; N-(4-Aminobenzoyl)glycine monosodium salt; EINECS 202-309-8; SUO3KVS1O9; Aminohippurate sodium [USP]; CHEBI:31204; Glycine, N-(4-aminobenzoyl)-, monosodium salt; HIPPURIC AC
    Click to Show/Hide
External Link
CID: 443971
TTD: D06OAV
 Compound Name Iodamide Approved [5]
Synonyms
Meglumine iodamide
    Click to Show/Hide
External Link
CID: 3723
TTD: D06LHU
DrugBank: DB08948
 Compound Name Iopentol Approved [5]
Synonyms
Imagopaque; 89797-00-2; Iopentolum [Latin]; UNII-7D6XWX076T; 7D6XWX076T; CPD. 5411; N,N'-Bis(2,3-dihydroxypropyl)-5-(N-(2-hydroxy-3-methoxypropyl)acetamido)-2,4,6-triiodoisophthalamide; 1,3-Benzenedicarboxamide, 5-(acetyl(2-hydroxy-3-methoxypropyl)amino)-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-; Iopentolum; Iopentol [USAN:BAN:INN]; Iopentol [USAN:INN:BAN]; N,N'-bis(2,3-dihydroxypropyl)-5-[N-(2-hydroxy-3-methoxypropyl)acetamido]-2,4,6-triiodoisophthalamide; Iopentol (USAN/INN); AC1L1K8R; SCHEMBL24471
    Click to Show/Hide
External Link
CID: 56016
TTD: D05MIL
DrugBank: DB13861
 Compound Name Tenapanor Phase 2 [7]
Synonyms
1234423-95-0; UNII-WYD79216A6; AZD 1722; WYD79216A6; AZD-1722; 3-((S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-N-(26-((3-((S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl)sulfonamido)-10,17-dioxo-3,6,21,24-tetraoxa-9,11,16,18-tetraazahexacosyl)benzenesulfonamide; Tenapanor [USAN:INN]; Tenapanor(free base); GTPL8449; CHEMBL3304485; SCHEMBL15267600; DTXSID40154016; BCP24892; BCP28554; EX-A2506
    Click to Show/Hide
External Link
CID: 71587953
TTD: D04TQO
DrugBank: DB11761
 Compound Name Cinacalcet Phase 3 [8]
Synonyms
Cinacalcet [INN]; AMG 073; AMG073; Cinacalcet (USAN); Mimpara (TN); Sensipar (TN); N-[(1R)-1-(1-naphthyl)ethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine; N-[(1R)-1-naphthalen-1-ylethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine; N-((1R)-1-(1-Naphthyl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine; N-((1R)-1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine; (R)-N-(1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine; (R)-alpha-methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethane amine
    Click to Show/Hide
External Link
CID: 156419
TTD: D03YGR
DrugBank: DB01012
 Compound Name Icodextrin Approved [5]
Synonyms
Extraneal
    Click to Show/Hide
External Link
CID: 3517
TTD: D02YCH
DrugBank: DB00629
 Compound Name BMP-7 bone morphogenetic protein Phase 4 [9]
Synonyms
BMP-2; BMP-7; Vascular calcification therapeutics, Johnson & Johnson; BMP-7 (kidney disease), Curis; BMP-7 (kidney disease), Stryker; Bone morphogenetic protein (BioChaperone technology, bone repair), Adocia; Bone morphogenetic protein (BioChaperone technology, degenerative disc disease/spinal fusion),Adocia; Bone morphogenic protein modulators (renal osteodystrophy/ vascular calcification), Johnson & Johnson; BMP-based therapeutics (renal osteodystrophy/ vascular calcification), Johnson & Johnson; BMP-based therapeutics (renal osteodystrophy/ vascular calcification), Ortho Biotech/Centocor
    Click to Show/Hide
External Link
TTD: D05LCN
 Compound Name CTAP101 Preregistration [10]
External Link
TTD: D03EWD
 Compound Name FG-4592 Phase 3 [11]
Synonyms
808118-40-3; Roxadustat; Roxadustat (FG-4592); UNII-X3O30D9YMX; N-[(4-Hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl]glycine; FG4592; ASP1517; Glycine, N-[(4-hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl]-; X3O30D9YMX; CHEMBL2338329; 2-[(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)amino]acetic acid; FG 4592; AK198953; n-((4-hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl)glycine; [[(4-Hydroxy-1-methyl-7-phenoxyisoquinolin-3-yl)carbonyl]amino]acetic Acid
    Click to Show/Hide
External Link
CID: 11256664
TTD: D03YKE
DrugBank: DB04847
 Compound Name 62Cu-ETS Phase 2 [12]
Synonyms
Copper-62-labeled PET renal perfusion imaging agent, Proportional Technologies; 62Cu-labeled PET renal perfusion imaging agent, Proportional Technologies
    Click to Show/Hide
External Link
TTD: D0X1XA
 Compound Name FG-2216 Phase 2 [13]
External Link
CID: 6914666
TTD: D0N6CS
DrugBank: DB08687
 Compound Name HD-003 Phase 2 [14]
Synonyms
NZ-419; Selective hydroxy radical modulator (chronic kidney disease), Hyundai/ Nippon Zoki
    Click to Show/Hide
External Link
TTD: D07ZMQ
 Compound Name NCX-4016 Discontinued in Phase 2 [15]
Synonyms
Nitroaspirin; Ncx 4016; NO-ASA; Nitric oxide-releasing aspirin; M-NO-ASA; M-NO-aspirin; [3-(nitrooxymethyl)phenyl] 2-acetyloxybenzoate; Benzoic acid, 2-(acetyloxy)-, 2-((nitrooxy)methyl)phenyl ester; Benzoic acid, 2-(acetyloxy)-, 3-((nitrooxy)methyl)phenyl ester; 2-((Nitrooxy)methyl)phenyl 2-(acetyloxy)benzoate; 2-Acetoxybenzoate-2-(1-nitroxymethyl)phenyl ester; 2-Acetoxybenzoic acid 3-(nitrooxymethyl)phenyl ester; 2-Acetoxybenzoic acid 3-nitrooxymethylphenyl ester; 3-((Nitrooxy)methyl)phenyl 2-(acetyloxy)benzoate; 3-(Nitroxymethyl)phenyl 2-acetoxybenzoate
    Click to Show/Hide
External Link
CID: 119032
TTD: D05OQX
DrugBank: DB12445
 Compound Name KD020 Phase 1/2 [16]
External Link
TTD: D0S7AW
 Compound Name ION532 Phase 1 [17]
Synonyms
AZD2373
    Click to Show/Hide
External Link
TTD: DR07FQ
 Compound Name LEO-27847 Phase 1 [18]
Synonyms
Renal system agent (kidney disease), LEO Pharma
    Click to Show/Hide
External Link
TTD: D0B0OA
 Compound Name PT-201 Phase 1 [19]
External Link
TTD: D08KDU
 Compound Name TAK-802 Discontinued in Phase 2 [20]
External Link
CID: 9888392
TTD: D03GAX
 Compound Name RG7641 Discontinued in Phase 1 [21]
External Link
TTD: D09LEB
 Compound Name ASP-0306 Discontinued in Phase 1 [22]
External Link
TTD: D05AQP
 Compound Name A-68828 Terminated [23]
Synonyms
A 68828; L-Cysteinamide, L-arginyl-L-cysteinyl-3-cyclohexyl-L-alanylglycylglycyl-L-arginyl-L-isoleucyl-L-alpha-aspartyl-L-arginyl-L-isoleucyl-L-phenylalanyl-L-arginyl-, cyclic(2-13)-disulfide
    Click to Show/Hide
External Link
CID: 25079032
TTD: D02NFA
 Compound Name CT-100 Investigative [24]
Synonyms
CT-100, CisThera; PAI-1 modulator (humanized antibody, kidney disease), CisThera; Plasminogen activator inhibitor-1 modulator (humanized antibody, kidney disease), CisThera
    Click to Show/Hide
External Link
CID: 12015870
TTD: D0X7LY
 Compound Name ZAMI-633 Investigative [24]
External Link
TTD: D0S6NH
 Compound Name INDUS-815B Investigative [25]
Synonyms
INDUS-815B (kidney disease); INDUS-815B (kidney disease), Indus Biotech; Protein kinase D-2 modulator (kidney disease),Indus Biotech
    Click to Show/Hide
External Link
TTD: D0O8FN
 Compound Name XEL-005OP Investigative [24]
External Link
TTD: D08NUS
 Compound Name ETR-001 Investigative [24]
External Link
TTD: D05TLQ
 Compound Name Recombinant human CFH protein Investigative [24]
Synonyms
Recombinant human CFH protein (AMD/renal disease); Recombinant human CFH protein (AMD/renal disease), Optherion; Recombinant human complement factor H protein (AMD/renal disease), Optherion
    Click to Show/Hide
External Link
TTD: D05GPN
 Compound Name AA-204 Investigative [26]
Synonyms
BMP agonist (chronic kidney disease), Thrasos Therapeutics
    Click to Show/Hide
External Link
TTD: D04JCT
References
Ref 1 METTL3/m(6)A/miRNA-873-5p Attenuated Oxidative Stress and Apoptosis in Colistin-Induced Kidney Injury by Modulating Keap1/Nrf2 Pathway. Front Pharmacol. 2019 May 15;10:517. doi: 10.3389/fphar.2019.00517. eCollection 2019.
Ref 2 The Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases. Biophys Rev. 2017 Feb;9(1):41-56. doi: 10.1007/s12551-016-0244-4. Epub 2016 Dec 6.
Ref 3 Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016). Expert Opin Ther Pat. 2017 Jul;27(7):763-785. doi: 10.1080/13543776.2017.1325464. Epub 2017 May 10.
Ref 4 NRF2 Regulation Processes as a Source of Potential Drug Targets against Neurodegenerative Diseases. Biomolecules. 2020 Jun 14;10(6):904. doi: 10.3390/biom10060904.
Ref 5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 6 Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63. doi: 10.1517/14728210902771334.
Ref 7 ClinicalTrials.gov (NCT01764854) Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis. U.S. National Institutes of Health.
Ref 8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3308).
Ref 9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4886).
Ref 10 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025617)
Ref 11 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8454).
Ref 12 ClinicalTrials.gov (NCT00714142) Renal Blood Flow Measurement With Positron Emission Tomography (PET). U.S. National Institutes of Health.
Ref 13 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018242)
Ref 14 ClinicalTrials.gov (NCT02378194) Change From Baseline to Chronic Kidney Disease Patient Before and After Administration Drug. U.S. National Institutes of Health.
Ref 15 Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90. doi: 10.1517/14728214.11.1.75.
Ref 16 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020855)
Ref 17 ClinicalTrials.gov (NCT04269031) A Phase I, First-in-Human, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2373 Following Single Ascending Dose Administrations to Healthy Male Subjects of African Ancestry. U.S.National Institutes of Health.
Ref 18 ClinicalTrials.gov (NCT01007383) LEO 27847 - A Study in Healthy Male Subjects. U.S. National Institutes of Health.
Ref 19 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800039895)
Ref 20 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020145)
Ref 21 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800039781)
Ref 22 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032662)
Ref 23 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003432)
Ref 24 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
Ref 25 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1489).
Ref 26 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1794).